U.S. FDA Approves Mylan and Biocon's Ogivri™, the First Biosimilar for Trastuzumab, for the Treatment of HER2-Positive Breast and Gastric Cancers

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. META
4. SPY
5. FDX
6. IBM
7. MU
8. ACN
9. USO
10. NVDA

Go back to U.S. FDA Approves Mylan and Biocon's Ogivri™, the First Biosimilar for Trastuzumab, for the Treatment of HER2-Positive Breast and Gastric Cancers
Mylan Inc. (NASDAQ: MYL) Delayed: 15.86 --0 (-0%)
Previous Close $15.86    52 Week High $55.51 
Open $10.56    52 Week Low $33.60 
Day High $15.86    P/E 10.43 
Day Low $15.86    EPS $1.52 
Volume 45,581       

Mylan Inc. (NASDAQ: MYL) Delayed: 15.86 --0 (-0%)
Previous Close $15.86    52 Week High $55.51 
Open $10.56    52 Week Low $33.60 
Day High $15.86    P/E 10.43 
Day Low $15.86    EPS $1.52 
Volume 45,581       

(NYSE: NSE) Delayed: 0.00 -22.48 (100%)
Previous Close $22.48    52 Week High $ 
Open $22.48    52 Week Low $ 
Day High $22.48    P/E N/A 
Day Low $22.48    EPS $ 
Volume 0